The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine

This version was published on 1 January 2010

Ann Clin Biochem 2010;47:17-28
doi:10.1258/acb.2009.009196
© 2010 Association for Clinical Biochemistry

 

This Article
Right arrow
Figures Only
Right arrow
Full Text
Right arrow

Full Text (PDF)

Right arrow
All Versions of this Article:

acb.2009.009196v1

47/1/17

most recent

Right arrow
Alert me when this article is cited
Right arrow
Alert me if a correction is posted
Services
Right arrow
Email this article to a friend
Right arrow

Similar articles in this journal

Right arrow
Similar articles in PubMed
Right arrow
Alert me to new issues of the journal
Right arrow
Download to citation manager
Right arrow
Google Scholar
Right arrow
Articles by Blackwell, S.
PubMed
Right arrow
PubMed Citation
Social Bookmarking

What’s this?

Review Articles


Scott Blackwell


Department of Clinical Biochemistry, Royal Infirmary, 84 Castle Street, Glasgow G4 0SF, UK


Email: Scottblackwell01{at}yahoo.co.uk

Asymmetric dimethylarginine (ADMA) is an endogenous competitiveinhibitor of nitric oxide synthase and an important cause ofendothelial dysfunction. Its increased plasma concentrationis associated with a variety of traditional cardiovascular riskfactors, and may mediate their effects on the vascular endothelium.ADMA is also an independent predictor of cardiovascular eventsand mortality, and predicts outcomes in critically ill patientsin the intensive care unit. This work has provided insightsinto the role of ADMA as an endogenous regulator of nitric oxidesynthesis. At present there is no specific therapy to modifyADMA concentration, but increasing interest and work on proteinarginine methyltransferases and dimethylarginine dimethylaminohydrolase,which synthesize and metabolize ADMA, respectively, might providenovel therapeutic targets.


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What’s this?